Indication

Prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplant

Prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplant refers to prophylactic intervention against human cytomegalovirus (CMV) replication and associated clinical disease in severely immunocompromised transplant recipients. Read more about Prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplant

2 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplant therapies.

Showing 1–2 of 2 drugs

PREVYMIS (letermovir)

ANTIVIRAL - CMV INFECTION·PREVENTION OF CMV DISEASE AFTER KIDNEY TRANSPLANTATION·+1
Merck Sharp & Dohme

PREVYMIS (letermovir)

ANTIVIRAL - CMV INFECTION·PREVENTION OF CMV DISEASE AFTER KIDNEY TRANSPLANTATION·+1
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with Prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplant preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplant.

Prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplant refers to prophylactic intervention against human cytomegalovirus (CMV) replication and associated clinical disease in severely immunocompromised transplant recipients.

In patients undergoing allogeneic hematopoietic stem cell transplantation, particularly those who are CMV-seropositive prior to conditioning, profound T-cell depletion and immunosuppressive therapy severely impair CMV-specific cell-mediated immunity.

This immunological deficit permits latent CMV to reactivate from cellular reservoirs, leading to systemic viremia and potential end-organ complications such as pneumonitis, enteritis, and hepatitis, as well as increased overall mortality.

Prophylaxis aims to maintain viral suppression and prevent progression to overt cytomegalovirus disease during the vulnerable post-engraftment recovery period.

Personalize your experience

Follow Prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplant and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it